Dr.med.sci. Lejla Alidžanović Nurkanović

Speaking Sessions



Dr. med. univ. – Medical University of Vienna (2012);

Dr. scient. med. – Medical University of Vienna (2018);


Work experience:       

Resident – Clinic for oncology and radiotherapy, University Clinical Center Tuzla (2014 – );

Teaching assistant – Department for histology, Faculty of Medicine, the University of Tuzla (2014 – );

            Medical doctor – Clinic for oncology, University Clinical Center Sarajevo (2013);

Research fellow – Surgical Research Laboratory of the Medical University of Vienna (2009 – 2013);



Platelet-Stored Angiogenesis Factors: Clinical Monitoring is Prone to Artifacts 
Disease Markers, 2011; 31(2): 55-65 
Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C 


Neoadjuvant Bevacizumab Persistently Inactivates VEGF at the Time of Surgery Despite Preoperative Cessation 
British Journal of Cancer, 2012; 107(6): 961-6 
Starlinger P, Alidzanovic L, Schauer D, Maier T, Nemeth C, Perisanidis B, Tamandl D, Gruenberger B, Gruenberger T, Brostjan C 


Clinical Evidence for Thrombospondin-1 as a Relevant Suppressor of Liver Regeneration 
Journal of Hepatology, 2013; 58(5): 1053-4 
Starlinger P, Schauer D, Alidzanovic L, Zikeli S, Gebhardt K, Luf F, Fleischmann E, Perisanidis B, Gruenberger B, Gruenberger T, Brostjan C 


Thrombocytes Correlate with Lymphangiogenesis in Human Esophageal Cancer and Mediate Growth of 
Lymphatic Endothelial Cells In Vitro.
PLoS One, 2013; 8(6): e66941
Schoppmann SF, Alidzanovic L, Schultheis A, Perkmann T, Brostjan C, Birner P 


Monocytes with Angiogenic Potential are Selectively Induced by Liver Resection and Accumulate Near the Site 
of Liver Regeneration 
BMC Immunology, 2014; 15:50 
Schauer D, Starlinger P, Zajc P, Alidzanovic L, Maier T, Buchberger E, Pop L, Gruenberger B, Gruenberger T, Brostjan C 


Plasma thrombospondin 1 as a predictor of postoperative liver dysfunction 
The British Journal of Surgery, 2015; 102(7): 826-36 
Starlinger P, Haegele S, Wanek D, Zikeli S, Schauer D, Alidzanovic L, Fleischmann E, Gruenberger B, Gruenberger T, Brostjan C. 


Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which 
predicts treatment response 
Oncoimmunology, 2016; 5(6): e1160185 Schauer D, Starlinger P, Alidzanovic L, Zajc P, Maier T, Feldman A, Padickakudy R, Buchberger E, Elleder V, Spittler A, Stift J, Pop L, Gruenberger B, Gruenberger T, Brostjan C



The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance Oncotarget 2016; 7(35): 57197-57212 Alidzanovic L, Starlinger P, Schauer D, Maier T, Feldman A, Buchberger E, Stift J, Koeck U, Pop L, Gruenberger B, Gruenberger T, Brostjan C


Conference Contributions:

Functional wound healing despite drastic VEGF inactivation after neoadjuvant bevacizumab therapy; 52. Austrian Surgical Congress (2011), Vienna, Austria


VEGF Anstieg nach Bevacizumab Therapie: Zelluläre Quellen und Ursachen? 54. Austrian Surgical Congress (2013) Vienna, Austria


TKIs in the first- and second-line treatment of mRCC – different tolerability and response; Renal Horizons Summit 2019, Frankfurt, Germany


Courses and Seminars:

ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology in Belgrade, Serbia (2018)

ESMO Preceptorship on Gastric Cancer, Valencia, Spain (2017)

ESMO Symposium on Immuno-Oncology: Advances in cancer immunotherapy; from vaccines to antibodies and cell therapies, Geneva, Switzerland (2013)

3rd Balkan and Eastern European Masterclass in Clinical Oncology, Croatia, Dubrovnik  (2013)